The Comprehensive Systematic Review of Relationship of Intravitreal Steroid Implants to the Progression of Cataracts and Glaucoma
Keywords:
Intravitreal Steroid Implant, Dexamethasone, Fluocinolone Acetonide, Cataract, Glaucoma, Intraocular Pressure, Ozurdex, Retisert, Iluvien, Systematic ReviewAbstract
Introduction: Intravitreal steroid implants, such as dexamethasone (DEX) and fluocinolone acetonide (FAc), represent a significant advancement in managing chronic, vision-threatening conditions like diabetic macular edema (DME), retinal vein occlusion (RVO), and non-infectious uveitis. While their sustained-release mechanism offers prolonged therapeutic effect, concerns persist regarding their association with the progression of steroid-induced cataracts and glaucoma, which are common ocular complications of corticosteroid therapy (Kuppermann et al., 2007; Kempen et al., 2011).
Methods: This systematic review screened and included studies based on stringent criteria: human studies of FDA-approved intravitreal steroid implants, with quantifiable outcomes on cataract and/or glaucoma progression, follow-up ≥6 months, and appropriate study designs (RCTs, cohort, case-control, systematic reviews). Data from 80 studies were extracted concerning implant type, patient characteristics, follow-up, cataract progression/surgery rates, intraocular pressure (IOP) elevation, glaucoma incidence, and association strength.
Results: The evidence demonstrates a clear and significant association between intravitreal steroid implants and both cataract and glaucoma progression, with risk profiles varying markedly by implant type. Fluocinolone acetonide implants (Retisert, Iluvien) showed the highest risk, with cataract surgery required in 64.6% to 100% of phakic eyes and IOP elevation ≥10 mmHg in 65-79% of patients over extended follow-up (Callanan et al., 2008; Goldstein et al., 2007; Jaffe et al., 2005). Dexamethasone implants (Ozurdex) presented a lower but still elevated risk: cataract-related adverse events in 67.9% vs. 20.4% sham (Boyer et al., 2014), and IOP elevation rates of 11-41%, though rarely requiring surgical intervention (Maturi et al., 2016). Key risk factors included phakic status for cataract, and Black race, pre-existing glaucoma, and baseline uveitis activity for glaucoma (Friedman et al., 2013; Kempen et al., 2015).
Discussion: The heterogeneity in outcomes is primarily explained by pharmacokinetics: FAc provides continuous release for 2.5-3 years, leading to cumulative toxicity, whereas DEX releases over 4-6 months, resulting in more transient effects. This necessitates a risk-stratified clinical approach, favoring DEX in phakic or glaucoma-prone patients, and considering FAc primarily in pseudophakic, low-glaucoma-risk patients requiring long-term control (Vieira et al., 2020; Liao et al., 2022). The long-term efficacy-safety balance, as seen in the MUST trial, indicates that while implants offer superior inflammation control, systemic therapy may yield better long-term visual acuity due to avoided ocular complications (Kempen et al., 2017).
Conclusion: Intravitreal steroid implants are effective but carry a substantial, implant-dependent risk of cataract and glaucoma. Fluocinolone acetonide implants pose the highest risk, while dexamethasone implants offer a more favorable safety profile. Clinical management must involve careful patient selection, rigorous pre-treatment assessment of risk factors, and diligent, long-term monitoring for cataract progression and IOP elevation.
References
A. Bajwa, K. Aziz, and C. Foster. “SAFETY AND EFFICACY OF FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT (0.59 Mg) IN BIRDSHOT RETINOCHOROIDOPATHY.” Retina, 2014.
A. Capone, M. Singer, D. Dodwell, R. Dreyer, K. Oh, D. Roth, J. Walt, L. C. Scott, and D. Hollander. “EFFICACY AND SAFETY OF TWO OR MORE DEXAMETHASONE INTRAVITREAL IMPLANT INJECTIONS FOR TREATMENT OF MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION (SHASTA STUDY).” Retina, 2014.
A. Eaton, S. Koh, Jaime Jimenez, and C. Riemann. “The USER Study: A Chart Review of Patients Receiving a 0.2 Μg/Day Fluocinolone Acetonide Implant for Diabetic Macular Edema.” Ophthalmology and Therapy, 2018.
A. Sudhalkar, A. Vasavada, D. Bhojwani, Viraj A. Vasavada, Shail A. Vasavada, Vaishali Vasavada, and Samaresh Srivastava. “Intravitreal Dexamethasone Implant as an Alternative to Systemic Steroids as Prophylaxis for Uveitic Cataract Surgery: A Randomized Trial.” Eye, 2019.
A. Vie, L. Kodjikian, A. Malclès, É. Agard, H. E. Chehab, and A. Russo. “Tolerance of Dexamethasone Intravitreal Implant in GAO Patients According to Their Initial Treatment and Repeated Intravitreal Injections,” 2015.
B. Kuppermann, M. Blumenkranz, J. Haller, George A. Williams, D. Weinberg, C. Chou, and S. Whitcup. “Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients with Persistent Macular Edema.” A M A Archives of Ophthalmology, 2007.
C. Lowder, R. Belfort, S. Lightman, C. Foster, M. Robinson, R. Schiffman, Xiao-Yan Li, Harry Cui, and S. Whitcup. “Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis.” A M A Archives of Ophthalmology, 2011.
D. Boyer, Y. Yoon, R. Belfort, F. Bandello, R. Maturi, A. Augustin, Xiao-Yan Li, Harry Cui, Y. Hashad, and S. Whitcup. “Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema.” Ophthalmology (Rochester, Minn.), 2014.
D. Callanan, G. Jaffe, Daniel F. Martin, P. A. Pearson, and T. Comstock. “Treatment of Posterior Uveitis with a Fluocinolone Acetonide Implant: Three-Year Clinical Trial Results.” A M A Archives of Ophthalmology, 2008.
D. Friedman, J. Holbrook, Husam Ansari, J. Alexander, A. Burke, S. Reed, J. Katz, J. Thorne, S. Lightman, and J. Kempen. “Risk of Elevated Intraocular Pressure and Glaucoma in Patients with Uveitis: Results of the Multicenter Uveitis Steroid Treatment Trial.” Ophthalmology (Rochester, Minn.), 2013.
D. Goldstein, D. Godfrey, A. Hall, D. Callanan, G. Jaffe, P. A. Pearson, D. Usner, and T. Comstock. “Intraocular Pressure in Patients with Uveitis Treated with Fluocinolone Acetonide Implants.” A M A Archives of Ophthalmology, 2007.
Dong Kyu Lee, Joo Yong Lee, Se Joon Woo, Y. Ji, and C. Lee. “Changes in Intraocular Pressure Following Intravitreal Dexamethasone Implant in Patients with History of Glaucoma Filtration Surgery.” Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, 2024.
E. Unsal, K. Eltutar, Pınar Sultan, and H. Gungel. “The Efficiency of Intravitreal Dexamethasone Implants in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion.” Journal of Ocular Pharmacology and Therapeutics, 2015.
E. Unsal, K. Eltutar, Pınar Sultan, S. Ö. Erkul, and O. A. Osmanbasoğlu. “Efficacy and Safety of Intravitreal Dexamethasone Implants for Treatment of Refractory Diabetic Macular Edema.” Korean Journal of Ophthalmology, 2017.
F. Butt, and H. Devonport. “Treatment of Non-Infectious Posterior Uveitis with Dexamethasone Intravitreal Implants in a Real-World Setting.” Clinical Ophthalmology, 2023.
F. Matonti, S. Pommier, F. Meyer, C. Hajjar, P. Merite, É. Parrat, H. Rouhette, O. Rebollo, and S. Guigou. “Long-Term Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Diabetic Macular Edema.” European Journal of Ophthalmology, 2016.
F. Pacella, E. Pacella, E. Trovato Battagliola, M. Malvasi, S. Z. Scalinci, P. Turchetti, M. Salducci, Luca Lucchino, and L. Arrico. “Efficacy and Safety of Intravitreal Fluocinolone Acetonide Microimplant (ILUVIEN®) in Patients with Chronic Diabetic Macular Edema: 1 Year Follow-up.” European Journal of Ophthalmology, 2021.
G. Garay-Aramburu, and Ángela Gómez-Moreno. “A 5-Year Follow-Up Study of the Treatment of Macular Edema Due to Retinal Vein Occlusion Using Dexamethasone Intravitreal Implants.” Journal of Ocular Pharmacology and Therapeutics, 2018.
G. Jaffe, R. McCallum, Brenda Branchaud, C. Skalak, Z. Butuner, and P. Ashton. “Long-Term Follow-up Results of a Pilot Trial of a Fluocinolone Acetonide Implant to Treat Posterior Uveitis.” Ophthalmology (Rochester, Minn.), 2005.
Giuseppe Querques, Michele Figus, Maddalena De Bernardo, Mario Damiano Toro, Magda Gharbiya, Valentina Gallinaro, Elena Strina, Vittorio Cacace, and M. Nicolò. “Safety Profile of Intravitreal Dexamethasone Implant to Manage Diabetic Macular Edema: A Systematic Review of Real-World Studies.” Ophthalmologica. Journal International d'ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 2025.
J. Blanc, C. Deschasse, L. Kodjikian, C. Dot, A. Bron, and C. Creuzot-Garcher. “Safety and Long-Term Efficacy of Repeated Dexamethasone Intravitreal Implants for the Treatment of Cystoid Macular Edema Secondary to Retinal Vein Occlusion with or Without a Switch to Anti-VEGF Agents: A 3-Year Experience.” Graefe's Archive for Clinical and Experimental Ophthalmology, 2018.
J. Haller, F. Bandello, R. Belfort, M. Blumenkranz, M. Gillies, J. Heier, A. Loewenstein, et al. “Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion Twelve-Month Study Results.” Ophthalmology (Rochester, Minn.), 2011.
J. Haller, F. Bandello, R. Belfort, M. Blumenkranz, M. Gillies, J. Heier, A. Loewenstein, et al. “Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion.” Ophthalmology (Rochester, Minn.), 2010.
J. Heo, B. Cho, D. Goldstein, Y. Sepah, D. Do, and Q. Nguyen. “FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT–KOYANAGI–HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety.” Retina, 2016.
J. Kempen, M. Altaweel, J. Holbrook, D. Jabs, T. Louis, E. Sugar, and J. Thorne. “Randomized Comparison of Systemic Anti-Inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial.” Ophthalmology (Rochester, Minn.), 2011.
J. Kempen, M. Altaweel, J. Holbrook, E. Sugar, J. Thorne, and D. Jabs. “Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant Vs Systemic Anti-Inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.” Journal of the American Medical Association (JAMA), 2017.
J. Kempen, M. Altaweel, Lea T. Drye, J. Holbrook, D. Jabs, E. Sugar, and J. Thorne. “Quality of Life and Risks Associated with Systemic Anti-Inflammatory Therapy Versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-Four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.” Ophthalmology (Rochester, Minn.), 2015.
J. Sheppard, Quan Dong Nguyen, D. Usner, and T. Comstock. “Post-Cataract Outcomes in Patients with Noninfectious Posterior Uveitis Treated with the Fluocinolone Acetonide Intravitreal Implant.” Clinical Ophthalmology, 2012.
John Hall. “Re: Das Et Al.: Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets (Ophthalmology 2015;122:1375-94).” Ophthalmology (Rochester, Minn.), 2016.
Josh Wallsh, Behnam Sharareh, and R. Gallemore. “Therapeutic Effect of Dexamethasone Implant in Retinal Vein Occlusions Resistant to Anti-VEGF Therapy.” Clinical Ophthalmology, 2016.
Jyotirmay Biswas, Mudit Tyagi, and Manisha Agarwal. “The 0.2-Μg/Day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis.” Ophthalmology Science, 2023.
Kai-Yang Chen, Hoi-Chun Chan, and Chi-Ming Chan. “Are Dexamethasone Implants a Safe and Effective Breakthrough in Uveitis Treatment? A Systematic Review and Meta-Analysis.” Steroids, 2025.
Khaled Moghib, Trisha Shivashankar, Abdallah Abunamoos, Al Hasan Mia, Izere Salomon, T. Ghanm, Ammar Salah, Mohamed A. Aldemerdash, and Mona I Elshamy. “Efficacy and Safety of Dexamethasone Versus Intravitreal Aflibercept Implants for Macular Edema: A Systematic Review and Meta-Analysis.” European Journal of Medical Research, 2025.
L. Joshi, Satish Yaganti, M. Gemenetzi, S. Lightman, Dan Lindfield, Vasilis Liolios, V. Menezo, E. Shao, and Simon R. J. Taylor. “Dexamethasone Implants in Retinal Vein Occlusion: 12-Month Clinical Effectiveness Using Repeat Injections as-Needed.” British Journal of Ophthalmology, 2013.
L. Meyer, and C. Schönfeld. “Secondary Glaucoma After Intravitreal Dexamethasone 0.7 Mg Implant in Patients with Retinal Vein Occlusion: A One-Year Follow-up.” Journal of Ocular Pharmacology and Therapeutics, 2013.
L. S. Gallén, Noemí Ruiz Del Río, J. M. Vilaplana‐Mora, F. Alarcón‐Correcher, Sonia Andreu Natividad, F. G. Ibor, and A. Duch-Samper. “Fluocinolone Acetonide Intravitreal Implant for the Treatment of Macular Edema: Long‐term Outcomes from a Single Tertiary Hospital.” Acta Ophthalmologica, 2022.
Lias Georgalas, Ioannis Tservakis, Eftychia Eleftheria Kiskira, P. Petrou, D. Papaconstantinou, and Menelaos Kanakis. “Efficacy and Safety of Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion Resistant to Anti-VEGF Therapy: A 12-Month Prospective Study.” Cutaneous and Ocular Toxicology, 2019.
M. Hasanreisoğlu, H. B. Özdemir, Kaan Özkan, Murat Yüksel, Z. Aktaş, H. T. Atalay, Ş. Özdek, and G. Gürelik. “Intravitreal Dexamethasone Implant in the Treatment of Non-Infectious Uveitis.” Turkish Journal of Ophthalmology, 2019.
M. Rehak, C. Busch, J. Unterlauft, C. Jochmann, and P. Wiedemann. “Outcomes in Diabetic Macular Edema Switched Directly or After a Dexamethasone Implant to a Fluocinolone Acetonide Intravitreal Implant Following Anti-VEGF Treatment.” Acta Diabetologica, 2019.
M. Sanford. “Fluocinolone Acetonide Intravitreal Implant (Iluvien®).” Drugs, 2013.
M. Singer, V. Sheth, S. Mansour, Brandon Coughlin, and V. Gonzalez. “Three-Year Safety and Efficacy of the 0.19-Mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.” Ophthalmology (Rochester, Minn.), 2022.
M. Soliman, J. Zarranz-Ventura, U. Chakravarthy, M. Mckibbin, C. Brand, G. Menon, H. Cilliers, et al. “UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION.” Retina, 2022.
M. Zola, Cristina Briamonte, U. Lorenzi, F. Machetta, F. Grignolo, and A. Fea. “Treatment of Refractory Uveitic Macular Edema: Results of a First and Second Implant of Long-Acting Intravitreal Dexamethasone.” Clinical Ophthalmology, 2017.
Matias Iglicki, C. Busch, Dinah Zur, Mali Okada, Miriana Mariussi, J. Chhablani, Z. Cebeci, et al. “DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study.” Retina, 2019.
Matthieu Jabbour, L. Kodjikian, Alexandre Bourdin, Marie-Bénédicte Rougier, Y. Serrar, M. Weber, Hélène Massé, et al. “Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network.” Journal of Personalized Medicine, 2024.
Meghan K. Berkenstock, T. A. Mir, Irfan R. Khan, Bryn M. Burkholder, Benjamin C. Chaon, A. S. Shifera, and J. Thorne. “Effectiveness of the Dexamethasone Implant in Lieu of Oral Corticosteroids in Intermediate and Posterior Uveitis Requiring Immunosuppression.” Ocular Immunology and Inflammation, 2020.
N. Dikmen, E. Vural, N. Yenerel, F. Dikkaya, E. Elibol, and Alev Koçkar. “Intravitreal Dexamethasone Implant Results in the Treatment of Non-Infectious Uveitis.” İstanbul Kuzey Klinikleri, 2022.
N. Park, Hyun Duck Kwak, C. Yoon, J. E. Lee, M. Sagong, Sang Joon Lee, J. E. Lee, Kun-Hyung Kim, and H. Kim. “One-Year Outcome of Intravitreal Dexamethasone Implant for Diabetic Macular Edema Patients.” Journal of the Korean Ophthalmological Society, 2019.
O. E. Yucel, Ertuğrul Can, H. Ozturk, H. Birinci, and Yuksel Sullu. “Dexamethasone Implant in Chronic Diabetic Macular Edema Resistant to Intravitreal Ranibizumab Treatment.” Ophthalmic Research, 2016.
P. Dugel, F. Bandello, and A. Loewenstein. “Dexamethasone Intravitreal Implant in the Treatment of Diabetic Macular Edema.” Clinical Ophthalmology, 2015.
R. Khoramnia, T. Peto, F. Koch, Simon R. J. Taylor, J. P. Castro de Sousa, Lauren Hill, C. Bailey, and U. Chakravarthy. “Safety and Effectiveness of the Fluocinolone Acetonide Intravitreal Implant (ILUVIEN): 3-Year Results from the European IRISS Registry Study.” British Journal of Ophthalmology, 2022.
R. Maturi, A. Pollack, H. Uy, M. Varano, A. M. Gomes, Xiao-Yan Li, Harry Cui, J. Lou, Y. Hashad, and S. Whitcup. “INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.” Retina, 2016.
R. Parrish, C. Traverso, K. Green, and R. Danis. “Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants.” Ophthalmic Surgery Lasers and Imaging Retina, 2016.
Rafael Vieira, B. Sousa‐Pinto, and L. Figueira. “Efficacy and Safety of Corticosteroid Implants in Non-Infectious Uveitis: A Systematic Review with Network Meta-Analysis.” Ocular Immunology and Inflammation, 2020.
Rehan M Hussain, T. Ciulla, L. Ciulla, Bethany Sink, and A. Harris. “EFFICACY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR REFRACTORY MACULAR EDEMA CAUSED BY RETINAL VEIN OCCLUSION.” Retinal Cases & Brief Reports, 2016.
Ryan B. Rush, D. Goldstein, D. Callanan, Beeran B. Meghpara, W. Feuer, and Janet L. Davis. “Outcomes of Birdshot Chorioretinopathy Treated with an Intravitreal Sustained-Release Fluocinolone Acetonide-Containing Device.” American Journal of Ophthalmology-Glaucoma, 2011.
S. Fraser-Bell, L. Lim, A. Campain, H. Mehta, Christine Aroney, J. Bryant, Ji Li, G. Quin, I. McAllister, and M. Gillies. “Bevacizumab or Dexamethasone Implants for DME: 2-Year Results (The BEVORDEX Study).” Ophthalmology (Rochester, Minn.), 2016.
S. Guigou, S. Pommier, F. Meyer, C. Hajjar, P. Merite, É. Parrat, H. Rouhette, O. Rebollo, and F. Matonti. “Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema.” Ophthalmologica, 2015.
S. K. Mishra, Ankur Gupta, S. Patyal, Santosh Kumar, K. Raji, Abhilasha Singh, and V. Sharma. “Intravitreal Dexamethasone Implant Versus Triamcinolone Acetonide for Macular Oedema of Central Retinal Vein Occlusion: Quantifying Efficacy and Safety.” International Journal of Retina and Vitreous, 2018.
S. Mahapatra, Anjalika Parhi, Pallavi Shree, and Anuja Mohanty. “Safety and Efficacy Profile of Intravitreal Ranibizumab Vs Dexamethasone in Treatment of Naïve Diabetic Macular Edema.” Indian Journal of Ophthalmology, 2023.
S. Mansour, Daniel F. Kiernan, D. Roth, David A. Eichenbaum, N. Holekamp, S. Kaba, and E. Werts. “Two-Year Interim Safety Results of the 0.2 Μg/Day Fluocinolone Acetonide Intravitreal Implant for the Treatment of Diabetic Macular Oedema: The Observational PALADIN Study.” British Journal of Ophthalmology, 2020.
S. Theodoropoulou, Abdallah A. Ellabban, R. Johnston, H. Cilliers, Q. Mohamed, and A. Sallam. “Short-Term Safety of Dexamethasone Implant for Treatment of Macular Edema Due to Retinal Vein Occlusion, in Eyes with Glaucoma or Treated Ocular Hypertension.” Graefe's Archive for Clinical and Experimental Ophthalmology, 2017.
Saeed Alshahrani, R. Dolz-Marco, R. Gallego-Pinazo, M. Diaz-llopis, and J. F. Arevalo. “INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF REFRACTORY MACULAR EDEMA IN RETINAL VASCULAR DISEASES: Results of the KKESH International Collaborative Retina Study Group.” Retina, 2016.
Salina Teja, Lauren Sawatzky, Theresa Wiens, D. Maberley, and P. Ma. “Ozurdex for Refractory Macular Edema Secondary to Diabetes, Vein Occlusion, Uveitis and Pseudophakia.” Canadian Journal of Ophthalmology-Journal Canadien D Ophtalmologie, 2019.
Shuai Ming, Kunpeng Xie, Mingzhu Yang, Huijuan He, Ya Li, and B. Lei. “Comparison of Intravitreal Dexamethasone Implant and Anti-VEGF Drugs in the Treatment of Retinal Vein Occlusion-Induced Oedema: A Meta-Analysis and Systematic Review.” BMJ Open, 2020.
Suji Yeo, Yoo-Ri Chung, Ji Hun Song, Bahram Bodaghi, and Sarah Touhami. “A Meta-Analysis of the Efficacy and Safety of the 0.19 Mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis.” Biomedicines, 2025.
T. Elhamaky. “Long-Term Efficacy of Dexamethasone Intravitreal Implant in the Treatment of Vogt-Koyanagi-Harada Disease Relapsing Posterior Uveitis.” Indian Journal of Ophthalmology, 2021.
T. Janetos, A. Koreishi, and Debra A Goldstein. “Long-Term Clinical Outcomes of the 0.18 Mg Fluocinolone Acetonide Intravitreal Implant Following Local Corticosteroid Burst in Noninfectious Uveitis.” Ocular Immunology and Inflammation, 2024.
T. Mathis, T. Lereuil, Amro Abukashabah, N. Voirin, A. Sudhalkar, A. Bilgic, P. Denis, C. Dot, and L. Kodjikian. “Long-Term Follow-up of Diabetic Macular Edema Treated with Dexamethasone Implant: A Real-Life Study.” Acta Diabetologica, 2020.
Tai-Chi Lin, Po-Chen Tseng, Tsui‐Kang Hsu, Hsin-Wei Huang, Yi-Ming Huang, Wen-Jung Lo, Chen-Yu Chao, and Yu-Chien Chung. “Same-Day Bilateral Intravitreal Dexamethasone Implants for the Treatment of Diabetic Macular Edema.” Ophthalmologica, 2023.
V. Krivosic, Anishta Bheekee, S. Michée, M. Delyfer, R. Tadayoni, and J. Korobelnik. “Dexamethasone Intravitreal Implants for Retinal Vein Occlusion in a Clinical Setting.” Acta Ophthalmologica, 2014.
V. Sangwan, bullet P Andrew Pearson, bullet Hemanth, Paul bullet, and T. Comstock. “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population.” Ophthalmology and Therapy, 2014.
VD Sweta, BN Shibi Dev, and R. Sandhya. “Secondary Glaucoma After Intravitreal Dexamethasone Implant (Ozurdex) Injection in Patients with Retinal Disorder: A Retrospective Study.” Indian Journal of Ophthalmology, 2022.
W. Kiddee, W. Kiddee, G. Trope, L. Sheng, L. Beltran-Agulló, Michael Smith, M. H. Strungaru, J. Baath, and Y. Buys. “Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review.” Survey of Ophthalmology, 2013.
W. Liao, Zhenyu Zhong, Guannan Su, Xiaojie Feng, and Peizeng Yang. “Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis.” Frontiers in Pharmacology, 2022.
W. Wei, You-xin Chen, Bojie Hu, Mingwei Zhao, Mei Han, H. Dai, H. Uy, et al. “Multicenter, Prospective, Randomized Study of Dexamethasone Intravitreal Implant in Patients with Center-Involved Diabetic Macular Edema in the Asia-Pacific Region.” Clinical Ophthalmology, 2021.
X. Gu, and H. Dai. “One Year Clinical Observation of Dexamethasone Intravitreal Implant (Ozurdex) in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion,” 2018.
Xiao-xia Li, Ningli Wang, Xiao-ling Liang, Gezhi Xu, Xiao-Yan Li, J. Jiao, J. Lou, and Y. Hashad. “Safety and Efficacy of Dexamethasone Intravitreal Implant for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in Chinese Patients: Randomized, Sham-Controlled, Multicenter Study.” Graefe's Archive for Clinical and Experimental Ophthalmology, 2017.
Y. Yang, C. Bailey, F. Holz, N. Eter, M. Weber, C. Baker, S. Kiss, et al. “Long-Term Outcomes of Phakic Patients with Diabetic Macular Oedema Treated with Intravitreal Fluocinolone Acetonide (FAc) Implants.” Eye, 2015.
Ye He, X. Ren, Bo-jie Hu, W. Lam, and Xiaorong Li. “A Meta-Analysis of the Effect of a Dexamethasone Intravitreal Implant Versus Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema.” BMC Ophthalmology, 2018.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Arsya Firdaus, Setiawan Arif Wibowo (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
